The 2023 Endpoints 11; Regeneron’s gene editing ambitions; GSK’s research revamp; Ripple effect of Dana-Farber, Brigham breakup; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

While an End­points crew as­sem­bled in Boston for End­points 11, one of our biggest projects of the year, the rest of the team held down the fort and de­liv­ered ex­cel­lent cov­er­age from oth­er cor­ners of the world. We take a look at Re­gen­eron’s bet on gene edit­ing de­liv­ery, GSK’s re­search re­vamp, the im­pact of the breakup be­tween Dana-Far­ber and Brigham and Women’s Hos­pi­tal, no­table start­up launch­es, and more.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.